CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The new online Learning Center with new content can still be found under the “Training” folder on ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...